- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02722408
Efficacy and Safety of Gemcabene in Patients With Homozygous Familial Hypercholesterolemia on Stable, Lipid-Lowering Therapy (COBALT-1)
June 3, 2020 updated by: NeuroBo Pharmaceuticals Inc.
A Phase 2 Open-Label, Dose-Finding Study to Assess the Efficacy, Safety, and Tolerability of Gemcabene in Patients With Homozygous Familial Hypercholesterolemia on Stable, Lipid Lowering Therapy (COBALT-1)
The purpose of this study was to assess the efficacy, safety, and tolerability of multiple doses of Gemcabene in patients with HoFH on stable, lipid-lowering therapy.
Study Overview
Study Type
Interventional
Enrollment (Actual)
8
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ontario
-
London, Ontario, Canada
- Robarts Research Institute
-
-
Quebec
-
Chicoutimi, Quebec, Canada
- Ecogene-21
-
Montreal, Quebec, Canada
- Montreal Heart Institute
-
-
-
-
-
Holon, Israel
- Wolfson Medical Center Internal Medicine Dept.
-
Jerusalem, Israel
- Center for Research, Prevention and Treatment of Atherosclerosis - Cardiology Department of Medicine Kiryat Hadassah
-
Safed, Israel
- Ziv Medical Center Internal Medicine Department
-
-
-
-
California
-
Beverly Hills, California, United States
- Westside Medical Associates of Los Angeles
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
17 years and older (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Provision of written and signed informed consent (by patient or legal guardian) prior to any study-specific procedure;
- Male or female ≥17 years of age at time of consent;
- Diagnosis of HoFH by genetic confirmation (including compound heterozygosity) or a clinical diagnosis based on either (1) a history of an untreated LDL-C concentration >500 mg/dL (12.92 mmol/L) together with either appearance of xanthoma before 10 years of age, or evidence of heterozygous familial hypercholesterolemia in both parents or, if history is unavailable, (2) LDL-C >300 mg/dL (7.76 mmol/L) on maximally tolerated lipid-lowering drug therapy;
- Currently on a stable, low-fat, low-cholesterol diet in combination with a pre-existing, regulatory-approved, not excluded lipid-lowering therapy (i.e., statins, monoclonal antibodies to PCSK9, cholesterol absorption inhibitors, bile acid sequestrants, or nicotinic acid, or any combination thereof) at a stable dose for at least 4 weeks prior to the Screening Visit;
- Fasting LDL-C value >130 mg/dL (3.36 mmol/L) at the Screening Visit;
- Physical examination, including vital signs, that is within normal limits or clinically acceptable to the Investigator;
- Weight ≥50 kg;
- Female patients must not be pregnant or lactating. Women of child-bearing potential must have a negative serum pregnancy test at the Screening Visit and negative urine dipstick on Day 1 prior to dosing in order to qualify for the study. Women who are surgically sterile or are clinically confirmed to be post-menopausal (i.e., documented amenorrhea for ≥1 year in the absence of other biological or physiological causes) are not considered to be of child-bearing potential; and
- Women of child-bearing potential must agree to use acceptable methods of contraception throughout the duration of the study and for 30 days after the last dose of study drug. For this study, double-barrier contraception is required.
Exclusion Criteria:
- Other forms of primary hyperlipoproteinemia and secondary causes of hypercholesterolemia (e.g., nephrotic syndrome or hypothyroidism);
- Abnormal liver function test at the Screening Visit (aspartate aminotransferase or alanine aminotransferase >2 × the upper limit of normal [ULN]; total bilirubin >1.5 × ULN; or alkaline phosphatase >2 × ULN based on appropriate age and gender normal values). Patients with bilirubin >1.5 × ULN and history of Gilbert's syndrome may be included; reflexive direct bilirubin testing will be used to confirm Gilbert's syndrome;
- Moderate (Grade B) or severe (Grade C) chronic hepatic impairment according to the Child Pugh classification;
- Active liver disease (e.g., cirrhosis, alcoholic liver disease, hepatitis B virus [HBV], hepatitis C virus [HCV], autoimmune hepatitis, liver failure, liver cancer), history of liver transplant, or known diagnosis of human immunodeficiency virus (HIV);
- Triglycerides value >400 mg/dL (4.52 mmol/L) at the Screening Visit;
- Moderate to severe renal insufficiency defined as an estimated GFR <30 mL/min/1.73m2 (calculated using The Chronic Kidney Disease Epidemiology Collaboration equation) at the Screening Visit;
- Abnormal urinalysis (proteinuria greater than trace or any male or non-menstruating female with greater than trace hematuria), confirmed by reflexive urine protein:creatinine ratio testing;
- Uncontrolled thyroid disease: hyperthyroidism or hypothyroidism as defined by thyroid stimulating hormone (TSH) below the lower limit of normal or >1.5 × ULN, respectively, at the Screening Visit. If controlled, treatment should be stable for at least 3 months prior to the Screening Visit;
- Type 1 diabetes mellitus or uncontrolled type 2 diabetes mellitus (hemoglobin A1c [HbA1c] value >8%), or any diabetic patient taking insulin and/or thiazolidinediones;
- New York Heart Association Class III or IV heart failure;
- Myocardial infarction, severe or unstable angina pectoris, coronary angioplasty, coronary artery bypass graft, or other major cardiovascular events resulting in hospitalization within 3 months of the Screening Visit. Patients with adequately treated stable angina, per Investigator assessment, may be included;
- Uncontrolled cardiac arrhythmia or prolonged QT on the Screening Visit or Day 1 prior to dosing ECG (QTcF >450 msec for men and >470 msec for women) or known family history of prolonged QT or unexplained sudden cardiac death;
- Uncontrolled hypertension, defined as sitting systolic blood pressure >180 mmHg or diastolic blood pressure >110 mmHg, and confirmed by repeat measurement;
- Currently receiving cancer treatments or, in the Investigator's opinion, at risk of relapse for recent cancer;
- Use of fibrate lipid-lowering agent 6 weeks prior to the Screening Visit;
- Hypersensitivity to or a history of significant adverse reactions to any fibrate lipid lowering agent;
- Use of apheresis (LDL or plasma) 8 weeks prior to the Screening Visit;
- Use of lomitapide 2 months prior to the Screening Visit;
- Use of mipomersen 5 months prior to the Screening Visit;
- Use of any excluded medications or supplements (e.g., potent cytochrome P450 [CYP] 3A4 inhibitors);
- History of drug or alcohol abuse within the past year or inability to comply with protocol requirements, including subject restrictions;
- Previously treated with gemcabene;
- Participation in another clinical study of an investigational agent or device concurrently or within 1 month prior to the Screening Visit, or use of an investigational agent within 1 month or 5 half-lives (if known), whichever is longer, prior to the Screening Visit; or
- Any other finding which, in the opinion of the Investigator, would compromise the patient's safety or participation in the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Gemcabene
Participants with homozygous familial hypercholesterolemia (HoFH) on stable lipid lowering therapy received 300 milligram (mg) of Gemcabene, orally once daily from day 1 to 28 followed by 600 mg of Gemcabene, orally once daily from day 29 to 56 followed by 900 mg of Gemcabene, orally once daily from day 57 to 84.
Participants were followed until Day 112.
|
300 mg tablet orally once daily for four weeks followed by 600 mg tablet orally once daily for four weeks followed by 900 mg tablet orally once daily for four weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percent Change From Baseline in LDL-C at Day 28
Time Frame: Baseline, day 28
|
Baseline, day 28
|
Percent Change From Baseline in LDL-C at Day 56
Time Frame: Baseline, day 56
|
Baseline, day 56
|
Percent Change From Baseline in LDL-C at Day 84
Time Frame: Baseline, day 84
|
Baseline, day 84
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in Fasting LDL-C
Time Frame: Baseline, days 28, 56 and 84
|
Baseline, days 28, 56 and 84
|
|
Percent Change From Baseline in Fasting Non-HDL-C
Time Frame: Baseline, days 28, 56 and 84
|
Baseline, days 28, 56 and 84
|
|
Change From Baseline in Fasting Non-HDL-C
Time Frame: Baseline, days 28, 56 and 84
|
Baseline, days 28, 56 and 84
|
|
Percent Change From Baseline in Fasting Total Cholesterol (TC)
Time Frame: Baseline, days 28, 56 and 84
|
Baseline, days 28, 56 and 84
|
|
Change From Baseline in Fasting Total Cholesterol (TC)
Time Frame: Baseline, days 28, 56 and 84
|
Baseline, days 28, 56 and 84
|
|
Percent Change From Baseline in Fasting Triglycerides (TG)
Time Frame: Baseline, days 28, 56 and 84
|
Baseline, days 28, 56 and 84
|
|
Change From Baseline in Fasting Triglycerides (TG)
Time Frame: Baseline, days 28, 56 and 84
|
Baseline, days 28, 56 and 84
|
|
Percent Change From Baseline in Fasting HDL-C
Time Frame: Baseline, days 28, 56 and 84
|
Baseline, days 28, 56 and 84
|
|
Change From Baseline in Fasting HDL-C
Time Frame: Baseline, days 28, 56 and 84
|
Baseline, days 28, 56 and 84
|
|
Percent Change From Baseline in Fasting VLDL-C
Time Frame: Baseline, days 28, 56 and 84
|
Baseline, days 28, 56 and 84
|
|
Change From Baseline in Fasting VLDL-C
Time Frame: Baseline, days 28, 56 and 84
|
Baseline, days 28, 56 and 84
|
|
Percent Change From Baseline in Fasting LDL-C as Per Receptor Mutation Status
Time Frame: Baseline, days 28, 56 and 84
|
Receptor mutation status was categorized as LDLr status and EAS clinical diagnosis of HoFH which was reported in this outcome measure.
|
Baseline, days 28, 56 and 84
|
Change From Baseline in Fasting LDL-C as Per Receptor Mutation Status
Time Frame: Baseline, days 28, 56 and 84
|
Receptor mutation status was categorized as LDLr status and EAS clinical diagnosis of HoFH which was reported in this outcome measure.
|
Baseline, days 28, 56 and 84
|
Percent Change From Baseline in Fasting Non-HDL-C as Per Receptor Mutation Status
Time Frame: Baseline, days 28, 56 and 84
|
Receptor mutation status was categorized as LDLr status and EAS clinical diagnosis of HoFH which was reported in this outcome measure.
|
Baseline, days 28, 56 and 84
|
Change From Baseline in Fasting Non-HDL-C as Per Receptor Mutation Status
Time Frame: Baseline, days 28, 56 and 84
|
Receptor mutation status was categorized as LDLr status and EAS clinical diagnosis of HoFH which was reported in this outcome measure.
|
Baseline, days 28, 56 and 84
|
Percent Change From Baseline in Fasting VLDL-C as Per Receptor Mutation Status
Time Frame: Baseline, days 28, 56 and 84
|
Receptor mutation status was categorized as LDLr status and EAS clinical diagnosis of HoFH which was reported in this outcome measure.
|
Baseline, days 28, 56 and 84
|
Change From Baseline in Fasting VLDL-C as Per Receptor Mutation Status
Time Frame: Baseline, days 28, 56 and 84
|
Receptor mutation status was categorized as LDLr status and EAS clinical diagnosis of HoFH which was reported in this outcome measure.
|
Baseline, days 28, 56 and 84
|
Percent Change From Baseline in Fasting HDL-C as Per Receptor Mutation Status
Time Frame: Baseline, days 28, 56 and 84
|
Receptor mutation status was categorized as LDLr status and EAS clinical diagnosis of HoFH which was reported in this outcome measure.
|
Baseline, days 28, 56 and 84
|
Change From Baseline in Fasting HDL-C as Per Receptor Mutation Status
Time Frame: Baseline, days 28, 56 and 84
|
Receptor mutation status was categorized as LDLr status and EAS clinical diagnosis of HoFH which was reported in this outcome measure.
|
Baseline, days 28, 56 and 84
|
Percent Change From Baseline in Fasting TC as Per Receptor Mutation Status
Time Frame: Baseline, days 28, 56 and 84
|
Receptor mutation status was categorized as LDLr status and EAS clinical diagnosis of HoFH which was reported in this outcome measure.
|
Baseline, days 28, 56 and 84
|
Change From Baseline in Fasting TC as Per Receptor Mutation Status
Time Frame: Baseline, days 28, 56 and 84
|
Receptor mutation status was categorized as LDLr status and EAS clinical diagnosis of HoFH which was reported in this outcome measure.
|
Baseline, days 28, 56 and 84
|
Percent Change From Baseline in Fasting TG as Per Receptor Mutation Status
Time Frame: Baseline, days 28, 56 and 84
|
Receptor mutation status was categorized as LDLr status and EAS clinical diagnosis of HoFH which was reported in this outcome measure.
|
Baseline, days 28, 56 and 84
|
Change From Baseline in Fasting TG as Per Receptor Mutation Status
Time Frame: Baseline, days 28, 56 and 84
|
Receptor mutation status was categorized as LDLr status and EAS clinical diagnosis of HoFH which was reported in this outcome measure.
|
Baseline, days 28, 56 and 84
|
Number of Participants Achieving LDL-C Reduction of ≥15%
Time Frame: Days 28, 56 and 84
|
Days 28, 56 and 84
|
|
Number of Participants Achieving LDL-C Reduction of ≥20%
Time Frame: Days 28, 56 and 84
|
Days 28, 56 and 84
|
|
Number of Participants Achieving LDL-C Reduction of ≥25%
Time Frame: Days 28, 56 and 84
|
Days 28, 56 and 84
|
|
Number of Participants Achieving LDL-C Reduction of ≥30%
Time Frame: Days 28, 56 and 84
|
Days 28, 56 and 84
|
|
Number of Participants Achieving an LDL-C Value <100 mg/dL (2.59 mmol/L)
Time Frame: Days 28, 56 and 84
|
Days 28, 56 and 84
|
|
Percent Change From Baseline in High-sensitivity C-reactive Protein (hsCRP)
Time Frame: Baseline, days 28, 56 and 84
|
Baseline, days 28, 56 and 84
|
|
Change From Baseline in High-sensitivity C-reactive Protein (hsCRP)
Time Frame: Baseline, days 28, 56 and 84
|
Baseline, days 28, 56 and 84
|
|
Percent Change From Baseline in Fibrinogen
Time Frame: Baseline, days 28, 56 and 84
|
Baseline, days 28, 56 and 84
|
|
Change From Baseline in Fibrinogen
Time Frame: Baseline, days 28, 56 and 84
|
Baseline, days 28, 56 and 84
|
|
Percent Change From Baseline in Fasting Lipoprotein(a)
Time Frame: Baseline, days 28, 56 and 84
|
Baseline, days 28, 56 and 84
|
|
Change From Baseline in Fasting Lipoprotein(a)
Time Frame: Baseline, days 28, 56 and 84
|
Baseline, days 28, 56 and 84
|
|
Percent Change From Baseline in Fasting Apolipoprotein B
Time Frame: Baseline, days 28, 56 and 84
|
Baseline, days 28, 56 and 84
|
|
Change From Baseline in Fasting Apolipoprotein B
Time Frame: Baseline, days 28, 56 and 84
|
Baseline, days 28, 56 and 84
|
|
Percent Change From Baseline in Fasting Apolipoprotein A-I
Time Frame: Baseline, days 28, 56 and 84
|
Baseline, days 28, 56 and 84
|
|
Change From Baseline in Fasting Apolipoprotein A-I
Time Frame: Baseline, days 28, 56 and 84
|
Baseline, days 28, 56 and 84
|
|
Percent Change From Baseline in Fasting Apolipoprotein A-II
Time Frame: Baseline, days 28, 56 and 84
|
Baseline, days 28, 56 and 84
|
|
Change From Baseline in Fasting Apolipoprotein A-II
Time Frame: Baseline, days 28, 56 and 84
|
Baseline, days 28, 56 and 84
|
|
Percent Change From Baseline in Fasting Apolipoprotein C-II
Time Frame: Baseline, days 28, 56 and 84
|
Baseline, days 28, 56 and 84
|
|
Change From Baseline in Fasting Apolipoprotein C-II
Time Frame: Baseline, days 28, 56 and 84
|
Baseline, days 28, 56 and 84
|
|
Percent Change From Baseline in Fasting Apolipoprotein C-III
Time Frame: Baseline, days 28, 56 and 84
|
Baseline, days 28, 56 and 84
|
|
Change From Baseline in Fasting Apolipoprotein C-III
Time Frame: Baseline, days 28, 56 and 84
|
Baseline, days 28, 56 and 84
|
|
Percent Change From Baseline in Fasting Apolipoprotein E
Time Frame: Baseline, days 28, 56 and 84
|
Baseline, days 28, 56 and 84
|
|
Change From Baseline in Fasting Apolipoprotein E
Time Frame: Baseline, days 28, 56 and 84
|
Baseline, days 28, 56 and 84
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 1, 2016
Primary Completion (Actual)
April 1, 2017
Study Completion (Actual)
July 1, 2017
Study Registration Dates
First Submitted
March 12, 2016
First Submitted That Met QC Criteria
March 23, 2016
First Posted (Estimate)
March 30, 2016
Study Record Updates
Last Update Posted (Actual)
June 25, 2020
Last Update Submitted That Met QC Criteria
June 3, 2020
Last Verified
June 1, 2020
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- GEM-201
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypercholesteremia
-
Ikaria Bioscience Pty LtdSHANGHAI RONA Therapeutics Co.,Ltd.Not yet recruitingTo Reduce the LDL-C Level in Hypercholesteremia Patients
-
Ikaria Bioscience Pty LtdRecruitingTo Reduce the LDL-C Level in Hypercholesteremia Adult Patients | Combination for Subgroup High LDL-c Patients With Other ComorbiditiesAustralia
-
NeuroBo Pharmaceuticals Inc.CompletedHypercholesteremiaUnited States
-
NeuroBo Pharmaceuticals Inc.Completed
-
University of IoanninaUniversity Hospital, IoanninaCompletedDyslipidemias | Endothelial Dysfunction | Children, Only | Renal Dysfunction | Hypercholesteremia in ChildrenGreece
-
The Cooper InstituteCargillCompleted
-
Jiangsu HengRui Medicine Co., Ltd.CompletedHypercholesteremiaChina
-
AstraZenecaCompletedHypercholesteremiaUnited States, France, Norway, Netherlands, Belgium, Germany, Finland, Czech Republic
-
AstraZenecaCompletedHypercholesteremiaBelgium
Clinical Trials on Gemcabene
-
NeuroBo Pharmaceuticals Inc.CompletedHypercholesterolemia
-
Elif OralCompletedFatty Liver | Hypertriglyceridemia | NASH - Nonalcoholic Steatohepatitis | Familial Partial LipodystrophyUnited States
-
NeuroBo Pharmaceuticals Inc.CompletedHypercholesterolemia | Hypertriglyceridemia
-
NeuroBo Pharmaceuticals Inc.CompletedSevere Hypertriglyceridemia | Mixed DyslipidaemiaUnited States, Canada
-
NeuroBo Pharmaceuticals Inc.CompletedHypercholesteremiaUnited States
-
Emory UniversityGemphire TherapeuticsTerminated
-
NeuroBo Pharmaceuticals Inc.Completed
-
NeuroBo Pharmaceuticals Inc.CompletedInsulin Sensitivity
-
NeuroBo Pharmaceuticals Inc.Completed
-
NeuroBo Pharmaceuticals Inc.Completed